Model points to silent C. diff spread in oncology units

A newly published modeling study suggests hospitals may be looking at the wrong patients when trying to stop C. difficile spread in oncology units. Investigators found that asymptomatic colonized patients were responsible for 92% of transmission events that led to new colonizations, while routine testing identified only 23% of those new colonization events. The paper was published online October 1, 2026, in Infection Control & Hospital Epidemiology. (cambridge.org)

The work focused on two high-risk units at Barnes-Jewish Hospital in St. Louis: a leukemia ward and a hematopoietic cell transplant unit. Researchers built a stochastic, individual-based network model using data from a prospective cohort study conducted between January 19 and July 22, 2019. Their framework tracked patients as susceptible, asymptomatically colonized, or infected with C. difficile, and also modeled room contamination and healthcare worker-mediated spread. A key challenge, the authors noted, is that testing data cover only a small fraction of patient-days, making the hidden burden of colonization easy to underestimate. (cambridge.org)

That hidden burden is central to the paper’s findings. Across all patient-days in the study, only 10.3% included at least one C. difficile test, and the authors said infection status could be assigned for only 9.1% of patient-days because negative EIA results do not rule out asymptomatic colonization. In the model, about half of newly identified colonization or infection events were linked to importation, meaning patients were already colonized or infected when they entered the room. Among transmission-driven events, asymptomatic colonized patients were the source in 92% of cases. (cambridge.org)

The results fit with a broader infection-control literature that has been pointing toward colonized patients as an underrecognized reservoir. CDC clinical guidance notes that colonization is more common than active infection and that colonized patients often have no symptoms. Updated acute-care prevention guidance also lists identification of asymptomatic carriers and use of contact precautions as an unresolved but actively considered strategy, especially in high-risk settings. (cdc.gov)

Some oncology clinicians have already described practical benefits from screening programs. In a 2024 Oncology Nursing Society review, an oncology nurse specialist wrote that cancer populations are at elevated risk for C. diff colonization because of antibiotic exposure, immunosuppression, and frequent healthcare contact. She also reported that, after her unit began identifying colonized hematology patients on admission, its hospital-acquired C. diff rate dropped by about 50%, though that experience reflects a single program rather than a randomized trial. (ons.org)

Why it matters: For veterinary professionals, especially those working in referral hospitals, oncology services, or intensive inpatient settings, the study offers a familiar infection-control lesson: the patients driving transmission may not be the ones showing obvious clinical signs. While this paper is in human medicine, the principle matters in veterinary epidemiology and hospital biosecurity, where asymptomatic carriage, environmental persistence, and staff-mediated spread also complicate control efforts. It also reinforces the value of distinguishing colonization from disease when interpreting test results, building surveillance programs, and deciding where to focus cleaning, isolation, and antimicrobial stewardship resources. (cambridge.org)

What to watch: The biggest next step is whether hospitals translate these modeling findings into targeted interventions, such as admission screening in selected oncology populations, modified contact precautions for carriers, or more aggressive sporicidal cleaning, and whether those approaches improve outcomes enough to justify the added cost and workflow demands. Existing guidance suggests the answer may vary by unit, baseline CDI burden, and local capacity. (infectioncontrol.ucsfmedicalcenter.org)